ALZN Alzamend Neuro Inc
Company Analysis
Latest News
🔴 Alzamend Neuro is trading 7.05% down in pre-market amid selling-stockholder offering of up to 98,388,305 shares
Alzamend Neuro is trading 7.05% down in pre-market at $1.45 after a filing disclosed an offering of up to 98,388,305 shares by selling stockholders. - The...
🔴 Alzamend Neuro is trading 6.1% down today as XBI falls 2.47%
Alzamend Neuro is trading at $1.53, down -6.13%, amid biotech-sector weakness. - No negative company-specific announcement was identified for August 21,...
🔴 Alzamend Neuro is trading 8% down in pre-market after sharp after-hours reversal
Alzamend Neuro is trading at $1.50, down 7.96% after a sharp after-hours reversal. - The stock closed at $1.63 on August 20, 2026. - The latest company news...
🔴 Alzamend Neuro is trading 10.43% down in after-hours trading as major indexes fell
Alzamend Neuro is trading 10.43% down at $1.46, aligned with broad risk-off sentiment after the August 20, 2026 regular session closed at $1.63. - No negative...
🔴 Alzamend Neuro is trading 7.36% down in after-hours trading amid likely broad risk-off pressure
Alzamend Neuro is trading 7.36% down now at $1.51 in after-hours trading, as broader risk-off sentiment likely pressured the stock. - The stock closed August...
🟢 Alzamend Neuro is trading 6.59% up today after AL001 findings accepted for Neuroscience 2026 poster
Alzamend Neuro is trading 6.59% up at $1.62 after announcing on August 20, 2026, that its AL001 Phase 1/2A resting-state fMRI findings were accepted for poster...
🟢 Alzamend Neuro is trading 7.24% up in pre-market after cancer-vaccine results lifted biotech sentiment
Alzamend Neuro is trading 7.24% up now at $1.63 in pre-market after positive late-stage personalized cancer-vaccine results from Moderna and Merck lifted...
🟢 Alzamend Neuro rises 5.3% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Alzamend Neuro is trading 5.7% down in pre-market
Alzamend Neuro is trading at $1.49, a -5.70% change, and appears to be driven by extended-hours trading pressure after the August 17 close of $1.58. • No...
🔴 Alzamend Neuro is trading 7.6% down in after-hours trading with no clear catalyst identified
Alzamend Neuro is trading 7.6% down at $1.46, with no clear company-specific catalyst identified for the after-hours decline. - Fell from the regular-session...
🟢 Alzamend Neuro is trading 5.5% up today
Alzamend Neuro is trading 5.5% up at $1.53, with no clear August 14, 2026 company-specific catalyst identified. - Recent coverage highlights an August 4...
🔴 Alzamend Neuro is trading 6.79% down in pre-market with no clear company-specific catalyst identified
Alzamend Neuro is trading 6.79% down now at $1.37 after no clear company-specific catalyst was identified for August 12, 2026. - The latest notable...
🟢 Alzamend Neuro is trading 5.3% up today as investors respond to financing
Alzamend Neuro is trading 5.3% up at $1.44 as investors continue responding to its recently announced financing. - The initial Series D convertible...
Alzamend Neuro Lands $7.5M Lifeline From an Affiliate Lender — But Can Convertible Preferred Stock Save a Company Worth Less Than the Cash It Just Raised?
Shares of Alzamend Neuro (ALZN) jumped 7.5% to $1.44 after the clinical-stage biotech disclosed a financing deal that dwarfs its own market value — raising...
🟢 Alzamend Neuro is trading 7.5% up today on $25M Series D financing deal
Alzamend Neuro is trading 7.5% up today at $1.44, extending gains following a $25 million Series D Convertible Preferred Stock agreement with an affiliate of...
Alzamend Neuro Secures up to $25M in Financing via Series D Preferred Stock Sale
Alzamend Neuro entered into a Securities Purchase Agreement with an affiliate, Ault Lending, LLC, to sell up to $25 million of its newly designated Series D...
🔴 Alzamend Neuro is trading 7% down today with no clear company-specific catalyst found
Alzamend Neuro is trading at $1.22 (-6.87%) in pre-market, extending a downward move from its $1.31 close on July 31 despite a lack of company-specific...
🔴 Alzamend Neuro is trading 5.2% down today with no clear catalyst
Alzamend Neuro is trading 5.2% down at $1.27 today following a quiet news flow with no fresh, company-specific developments or filings identified this...
🔴 Alzamend Neuro is trading 5.2% down today with no company-specific catalyst
Alzamend Neuro is trading at $1.27 (-5.22%) in pre-market after a quiet session with no company-specific catalyst found in available news. • Broader markets...
🔴 Alzamend Neuro is trading 6% down today on an earnings preview projecting zero revenue and a $0.67 EPS loss
Alzamend Neuro is trading at $1.26 (-5.97%) as investors position themselves ahead of the company's July 28, 2026, earnings report. • The Q2 2026 earnings...